drug · small molecule
brincidofovir
Marketedupdated 3mo agoby SymBio Pharmaceuticals Ltd🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for smallpox and viral disease and 6 investigational indications.
targets
DNA polymerase
all catalysts(1)
Trials studying brincidofovir
- phase3A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT
- phase2A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
- phase1Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
- phase2Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 4, 2028
~1.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Oct 10, 2034method-of-use (U-3165)US 10112909
- Oct 10, 2034formulationUS 10487061
- Oct 10, 2034compositionUS 8962829
- Oct 10, 2034formulationUS 9371344
- Aug 31, 2031compositionUS 9303051
- Aug 31, 2031compositionUS 9303051
FDA exclusivities (2)
- Jun 4, 2028ODE-354Orphan Drug (7y)1.8y
- Jun 4, 2028ODE-354Orphan Drug (7y)1.8y
News(1)
- Narcan maker Emergent BioSolutions eliminates top R&D role in sweeping restructuringTwo and a half years into his tenure as Emergent BioSolutions CEO, Joseph Papa is executing another round of restructuring to align the business with “current business realities.”fiercebiotech · 9d ago
Data sources
last refreshed 25m ago
Found something off?
comments(0)
5-min edit window · permanent after that